ESR1 and neoplasm: Compared to the pathologically Tis or T1, node negative WBI cohort, the S-PBI patients had younger age (p <0.01), lower tumor grade (p <0.01), less lymphovascular invasion (p <0.01), and more estrogen receptor positivity (p <0.01) (Table S1).